Efficacy and safety of sacituzumab govitecan in patients with
metastatic metaplastic triple-negative breast cancer: a
multinational retrospective case series from CEBCC-102 study

J 2025

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Miroslava MALEJCIKOVA; Miloš HOLÁNEK et al.

Základní údaje

Originální název

Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Autoři

Vydání

Breast Cancer Research and Treatment, New York, Springer, 2025, 0167-6806

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.000 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Sacituzumab govitecan; Antibody-drug conjugate; Triple-negative breast cancer; Metaplastic breast cancer; Real-world evidence

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 3. 2026 11:08, Mgr. Tereza Miškechová

Anotace

V originále

BackgroundMetastatic metaplastic triple-negative breast cancer (mMpTNBC) is a rare, aggressive subtype with poor responsiveness to standard therapies. Sacituzumab govitecan (SG) is effective in metastatic TNBC (mTNBC), but data in mMpTNBC are limited to case reports. Patients and methods: This multinational, multicenter, retrospective case series was conducted within the CEBCC-102 real-world evidence project across 18 cancer centers. Female patients with histologically confirmed mMpTNBC treated with >= 2L SG outside of clinical trials in Poland, the Czech Republic and Slovakia between August 2021 and June 2025 were included. Clinical data, treatment outcomes, and adverse events (AEs) were collected from medical records and analysed.ResultsAmong 303 patients with mTNBC treated with SG in second and later lines within the CEBCC-102 project, 13 women (4.3%) had mMpTNBC and were included in this analysis. Median age was 58 years. PD-L1 CPS >= 10 was found in 83% of tested cases. Overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. Neutropenia (N = 9, 69%) was the most common AE; no febrile neutropenia or treatment discontinuations due to toxicity occurred.ConclusionsThis first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1-positive disease.

Citovat

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Miroslava MALEJCIKOVA; Miloš HOLÁNEK; Renata SOUMAROVA; Aleksandra KONIECZNA; Iwona DANIELEWICZ; Maja LISIK-HABIB; Aleksandra LACKO; Marcin KUBECZKO; Renata PACHOLCZAK-MADEJ; Zuzana BIELCIKOVA a Miroslawa PUSKULLUOGLU. Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study. Breast Cancer Research and Treatment. New York: Springer, 2025, roč. 215, č. 1, s. 1-8. ISSN 0167-6806. Dostupné z: https://doi.org/10.1007/s10549-025-07875-4.

@article{2557771,
   author = {Zubrowska, Justyna and Pieniazek, Malgorzata and PolakiewiczandGilowska, Anna and Malejcikova, Miroslava and Holánek, Miloš and Soumarova, Renata and Konieczna, Aleksandra and Danielewicz, Iwona and LisikandHabib, Maja and Lacko, Aleksandra and Kubeczko, Marcin and PacholczakandMadej, Renata and Bielcikova, Zuzana and Puskulluoglu, Miroslawa},
   article_location = {New York},
   article_number = {1},
   doi = {https://doi.org/10.1007/s10549-025-07875-4},
   keywords = {Sacituzumab govitecan; Antibody-drug conjugate; Triple-negative breast cancer; Metaplastic breast cancer; Real-world evidence},
   language = {eng},
   issn = {0167-6806},
   journal = {Breast Cancer Research and Treatment},
   title = {Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study},
   url = {https://www.springermedizin.de/efficacy-and-safety-of-sacituzumab-govitecan-in-patients-with-me/51812276},
   volume = {215},
   year = {2025}
}

TY  - JOUR
ID  - 2557771
AU  - Zubrowska, Justyna - Pieniazek, Malgorzata - Polakiewicz-Gilowska, Anna - Malejcikova, Miroslava - Holánek, Miloš - Soumarova, Renata - Konieczna, Aleksandra - Danielewicz, Iwona - Lisik-Habib, Maja - Lacko, Aleksandra - Kubeczko, Marcin - Pacholczak-Madej, Renata - Bielcikova, Zuzana - Puskulluoglu, Miroslawa
PY  - 2025
TI  - Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study
JF  - Breast Cancer Research and Treatment
VL  - 215
IS  - 1
SP  - 1-8
EP  - 1-8
PB  - Springer
SN  - 01676806
KW  - Sacituzumab govitecan
KW  - Antibody-drug conjugate
KW  - Triple-negative breast cancer
KW  - Metaplastic breast cancer
KW  - Real-world evidence
UR  - https://www.springermedizin.de/efficacy-and-safety-of-sacituzumab-govitecan-in-patients-with-me/51812276
N2  - BackgroundMetastatic metaplastic triple-negative breast cancer (mMpTNBC) is a rare, aggressive subtype with poor responsiveness to standard therapies. Sacituzumab govitecan (SG) is effective in metastatic TNBC (mTNBC), but data in mMpTNBC are limited to case reports. Patients and methods: This multinational, multicenter, retrospective case series was conducted within the CEBCC-102 real-world evidence project across 18 cancer centers. Female patients with histologically confirmed mMpTNBC treated with >= 2L SG outside of clinical trials in Poland, the Czech Republic and Slovakia between August 2021 and June 2025 were included. Clinical data, treatment outcomes, and adverse events (AEs) were collected from medical records and analysed.ResultsAmong 303 patients with mTNBC treated with SG in second and later lines within the CEBCC-102 project, 13 women (4.3%) had mMpTNBC and were included in this analysis. Median age was 58 years. PD-L1 CPS >= 10 was found in 83% of tested cases. Overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. Neutropenia (N = 9, 69%) was the most common AE; no febrile neutropenia or treatment discontinuations due to toxicity occurred.ConclusionsThis first international real-world series of SG in mMpTNBC shows clinically relevant activity and manageable toxicity, addressing a critical evidence gap and supporting further prospective studies, particularly in PD-L1-positive disease.
ER  -

ZUBROWSKA, Justyna; Malgorzata PIENIAZEK; Anna POLAKIEWICZ-GILOWSKA; Miroslava MALEJCIKOVA; Miloš HOLÁNEK; Renata SOUMAROVA; Aleksandra KONIECZNA; Iwona DANIELEWICZ; Maja LISIK-HABIB; Aleksandra LACKO; Marcin KUBECZKO; Renata PACHOLCZAK-MADEJ; Zuzana BIELCIKOVA a Miroslawa PUSKULLUOGLU. Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study. \textit{Breast Cancer Research and Treatment}. New York: Springer, 2025, roč.~215, č.~1, s.~1-8. ISSN~0167-6806. Dostupné z: https://doi.org/10.1007/s10549-025-07875-4.

Přehled o publikaci